10 results
Left Atrial Appendage Closure after Ablation for Atrial Fibrillation - the OPTION Trial
17 Nov 2024
Alessandro Sticchi provides his take on the OPTION Trial presented at AHA 2024 in Chicago.

Author
Efficacy and safety of Edoxaban in anticoagulant therapy early after surgical bioprosthetic valve replacement: ENBALV trial
16 Nov 2024
Edoardo Zancanaro provides his take on the ENBALV trial presented by Chisato Izumi at AHA 2024 in Chicago.

Author
GLORIOUS - Efficacy of restrictive versus liberal oxygenation or Exenatide in patients undergoing coronary artery bypass grafting or aortic valve replacement – a randomised clinical trial
21 Nov 2024
Edoardo Zancanaro provides his take on the GLORIOUS trial presented by Sebastian Wiberg at AHA 2024 in Chicago.

Author
The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone versus placebo in patients with myocardial infarction
18 Nov 2024
Mirvat Alasnag provides her take on the CLEAR SYNERGY trial presented by Sanjit S Jolly at AHA 2024 in Chicago.

Author
SEISMIC-HF I - Exploring non-invasive methods for monitoring intracardiac filling pressures
16 Nov 2024
Luis Ortega provides his take on the SEISMIC-HF I study presented by Liviu Klein at AHA 2024, in Chicago.

Author
AHA 2024: get the interventional cardiology perspective!
13 Nov 2024
Stay up to date with what is new and hot in interventional cardiology at #AHA24 in Chicago.
Dapagliflozin in acute myocardial infarction: Cardiometabolic benefits without impact on cardiovascular death or heart failure hospitalization: The jury is still out
14 Nov 2023
Luis Ortega Paz provides his take on DAPA-MI - A registry-based randomized trial of dapagliflozin in patient with acute myocardial infarction without diabetes, which was presented by Stefan James at AHA 2023 in Philadelphia.

Author
Half-dose tenecteplase or primary PCI in older patients with ST-elevation myocardial infarction: The STREAM-2 1-year mortality follow-up results
15 Nov 2023
Aaysha Cader interviews Peter Sinnaeve on the STREAM-2 1-year mortality follow-up results, which were presented at the AHA 2023 Congress in Philadelphia.
Results suggest that a pharmaco-invasive strategy provides an alternative for older STEMI patients unable to undergo primary PCI.

Author

Author
ORBITA-2 - Percutaneous coronary intervention for stable angina: A randomized, placebo-controlled trial
12 Nov 2023
Luis Ortega Paz interviews Rasha Al-Lamee and Christopher Rajkumar on the results of ORBITA-2 randomized placebo-controlled trial, which were presented at the AHA 2023 Congress in Philadelphia.

Author

Author

Author
AHA 2023: get the interventional cardiology perspective!
11 Nov 2023
Stay up to date with what is new and hot in interventional cardiology at #AHA23 in Philadelphia.